← board
DYAI
distress 5/10 · elevated risk$1.25-4%today-15% from 52w high
Lead: Life sciences
Revenue
pre-revenue
Liquidity
$6M
Runway
1.0 yrs
Shares 1y
+1%
Price & events
+37.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.8%
1D
+5.0%
1W
+54.3%
1M
+43.7%
3M
+38.9%
6M
+13.6%
1Y
-10.1%
2Y
-65.0%
5Y
-75.8%
All
Overview
- Market Cap
- $45.55M
- Volume
- 39.36K
- 52 Week Range
- $0.68 – $1.47
- Total Shares
- 36.44M
- Float Shares
- 27.37M
- Short %
- 0.57%
- % Held by Insiders
- 25.53%
- % Held by Institutions
- 14.96%
- RVOL
- 0.16x
- Beta
- 1.15
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 8
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-05-28partnershipCollaboration to evaluate monoclonal antibody and vaccine candidates against hantaviruses including Andes virus, leveraging C1 platform.SEC 8-K
- late 2025conferencedata presentationsecondaryNon-Animal Dairy Enzymes (Inzymes) · Launch of first enzyme targeted for late 2025SEC 8-K
- late 2025 and early 2026conferencedata presentationsecondaryRecombinant Human Albumin · Commercial launch targeted for late 2025 and early 2026SEC 8-K
- 2025-09-30partnershipNon-Animal Dairy Enzymes · Received $250,000 milestone payment from Inzymes in Q3 2025SEC 8-K
- 2025-09-30partnershipRecombinant Human Albumin · Achieved $500,000 milestone in Proliant partnership in Q3 2025SEC 8-K
- 2025-03-20partnershipC1 · CEPI grant to accelerate protein-based vaccinesSEC 8-K
- 2024-11-16partnershipGrant from Bill & Melinda Gates Foundation for cell line development of monoclonal antibodies targeting RSV and malariaSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-11-14HC Wainwright & Co.Buy
- 2024-07-08HC Wainwright & Co.Buy
Competitors — Life sciences
- none identified
Recent news
- 2026-07-21Form 144 Dyadic International Inc For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21Form 144 Dyadic International Inc For: 21 July By Investing.com - Investing.com Canada
- 2026-07-21DYADIC INTERNATIONAL INC SEC Filing (Jul 21, 2026) - Stock Titan
- 2026-07-16Dyadic expands bio-industrial pipeline with cellulose enzyme By Investing.com - Investing.com South Africa
- 2026-07-16Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program - GlobeNewswire
- 2026-07-16Dyadic’s New Enzyme Program Targets Pulp, Paper and Biofuels - Stock Titan
- 2026-07-16Dyadic International, Inc. - Via Ritzau
- 2026-07-13Price to sales forward of Dyadic International, Inc. – NASDAQ:DYAI - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.